Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -32,670 | -20,819 | -8,614 | -17,653 | -7,649 |
| Depreciation Amortization | 188 | 153 | 116 | 67 | 330 |
| Accounts payable and accrued liabilities | -758 | -703 | -646 | -321 | -850 |
| Other Working Capital | 262 | 894 | -731 | -229 | -2,695 |
| Other Operating Activity | 13,284 | 6,564 | 1,771 | 14,347 | -1,430 |
| Operating Cash Flow | $-19,694 | $-13,911 | $-8,104 | $-3,789 | $-12,294 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -186 | -128 | -78 | -8 | -11 |
| Investing Cash Flow | $-186 | $-128 | $-78 | $-8 | $-11 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 33,101 | 33,100 | 33,052 | 49 | 50,145 |
| Common Stock Repurchased | -1,668 | -1,429 | -47 | -47 | -380 |
| Financing Cash Flow | $31,433 | $31,671 | $33,005 | $2 | $49,765 |
| Beginning Cash Position | 48,839 | 48,839 | 48,839 | 48,839 | 11,379 |
| End Cash Position | 60,392 | 66,471 | 73,662 | 45,044 | 48,839 |
| Net Cash Flow | $11,553 | $17,632 | $24,823 | $-3,795 | $37,460 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,694 | -13,911 | -8,104 | -3,789 | -12,294 |
| Capital Expenditure | -186 | -128 | -78 | -8 | -11 |
| Free Cash Flow | -19,880 | -14,039 | -8,182 | -3,797 | -12,305 |